October 23, 2017 2:49 PM ET

Pharmaceuticals

Company Overview of Modra Pharmaceuticals B.V.

Company Overview

Modra Pharmaceuticals B.V., a clinical-stage company, designs and develops oral formulations of commonly used anti-cancer drugs that are available in intravenous (IV) forms. It offers Docetaxel and Paclitaxel that are anticancer drugs and members of the taxane class of chemotherapeutics are part of the treatment practices for various cancer indications. The company was founded in 2010 and is based in Amsterdam, the Netherlands.

Louwesweg 6

Amsterdam,  1066 EC

Netherlands

Founded in 2010

Phone:

31 20 512 4734

Key Executives for Modra Pharmaceuticals B.V.

Chief Executive Officer
Chief Medical Officer
Compensation as of Fiscal Year 2017.

Modra Pharmaceuticals B.V. Key Developments

Modra Pharmaceuticals Announces Start of Phase II Study for Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer

Modra Pharmaceuticals announced the initiation and the inclusion of the first patients in a Phase II study of its lead compound, ModraDoc006/r, in metastatic castration-resistant prostate cancer patients to investigate its safety, feasibility and pharmacokinetic profile. ModraDoc006/r is a proprietary oral formulation of docetaxel (ModraDoc006) co-administered with boosting-agent ritonavir (r) to enhance the chemotherapy’s bioavailability. Chemotherapy remains an integral part of current cancer treatment regimens and achieving its oral delivery while retaining both efficacy and safety could significantly improve the therapeutic landscape for treating many types of cancer. The Phase II multi-center study will investigate safety and establish a feasible dosing regimen of ModraDoc006/r in chemotherapy naïve patients with metastatic castration-resistant prostate cancer for whom treatment with intravenous (IV) docetaxel is indicated. The study will enroll 20 patients and includes dose-escalation aiming to define the maximum tolerated dose that can be safely administered in a bi-daily weekly schedule without interruptions. Pharmacodynamics will be determined as secondary outcome measures. The first patients have already been treated as part of the trial. Modra Pharmaceuticals’ technology has been developed to address an unmet need for improving patient convenience while maintaining chemotherapy’s effectiveness. As the lead program in the Company’s pipeline, ModraDoc006/r has successfully been tested in Phase I clinical trials in patients with solid tumors.

Similar Private Companies By Industry

Company Name Region
Allgen Pharmaceuticals & Generics B.V. Europe
Alzheimer Research Centrum BV Europe
Angita B.V. Europe
AquaCultura B.V. Europe
Arcarios B.V. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Modra Pharmaceuticals B.V., please visit www.modrapharmaceuticals.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.